CHM
Price sensitive
Chimeric receives $1.8 M advance on FY26 R&D tax incentive
Chimeric Therapeutics Ltd
No summary is available for this announcement — open the PDF to read it in full.
Sign in for more about this company, including guidance changes and other insights.
Sign in